Drugmakers to raise US prices on over 250 medicines
Almost exactly 10 years after the FDA’s initial FDA approval for Bristol Myers Squibb’s Opdivo as the first PD-1 inhibitor in ...
The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...
Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $56.56 which represents a slight increase of $0.50 or 0.89% from the prior close of $56.06. The stock opened at $56.07 and ...
In a report released today, Akash Tewari from Jefferies maintained a Buy rating on Bristol-Myers Squibb (BMY – Research Report), with a price ...
While the New Year's tradition of drug price hikes has held firm for years, pharma companies have decidedly tamped down on ...
We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024. In this article, we are going to take a ...
The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...
Bristol-Myers Squibb has rebounded strongly in 2024, driven by key drug approvals and positive financial performance. See why ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback